SHIM
LTRN icon

Stone House Investment Management’s Lantern Pharma LTRN Stock Holding History

Stone House Investment Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$1.76K – 415
2024
Q1 		$1.76K Buy
+200
New +$1.07K ﹤0.01% 356

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Stone House Investment Management's LTRN Position: Q2 2024 in Review

Stone House Investment Management sold out of Lantern Pharma (LTRN) in Q2 2024, closing a stake of 200 shares — an estimated $1.76K sold.

Stone House Investment Management first reported a position in LTRN in Q1 2024 and held it in 1 quarter. The position peaked at $1.76K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2024.

  • Stone House Investment Management reported no remaining Lantern Pharma position as of Q2 2024 after selling out during the quarter.
  • Stone House Investment Management sold 200 Lantern Pharma shares in Q2 2024, an estimated $1.76K.
  • Stone House Investment Management first reported a position in Lantern Pharma in Q1 2024 and held it in 1 quarter.
  • Stone House Investment Management's Lantern Pharma position peaked at $1.76K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2024.

Based on Stone House Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.